Business Context and Reporting Period
Company: MUSTANG BIO, INC. (MBIO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Mustang Bio is a clinical-stage biopharmaceutical company focused on CAR T cell therapies for hematologic malignancies and solid tumors. The company is a majority-controlled subsidiary of Fortress Biotech, Inc. It has no approved products and has not generated any product revenue to date.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1.41) million | $(10.06) million | $(14.80) million | $(42.99) million |
| Operating Expenses | $1.46 million | $10.31 million | $15.23 million | $40.52 million |
| Cash & Equivalents (Sep 30, 2024) | $3.53 million | |||
| Total Assets (Sep 30, 2024) | $7.19 million | |||
| Stockholders' Equity (Sep 30, 2024) | $(8.66) million (Deficit) | |||
| Accumulated Deficit | $(395.77) million |
Material Changes vs. Prior Period
- Significant Expense Reduction: Total operating expenses decreased by 86% in Q3 2024 compared to Q3 2023, driven primarily by an 81% workforce reduction in April 2024 and the termination of several license agreements (St. Jude, Leiden University Medical Centre, Mayo Clinic).
- Asset Impairment: The company recorded a $2.65 million asset impairment charge in the first nine months of 2024 related to leasehold improvements and right-of-use assets, reflecting the strategic pivot and facility changes.
- Facility Transaction: Following a CFIUS-mandated abandonment of a facility sale to uBriGene, the company repurchased certain assets in June 2024. Approximately $2.2 million of these assets are classified as "held for sale."
- Financing Activity: The company raised approximately $5.3 million in net proceeds from equity offerings in May and June 2024. In October 2024 (subsequent event), the company raised an additional ~$4.0 million via warrant exercises.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for the 12 months following the issuance of these financial statements. Continued operations depend on raising additional capital.
- Liquidity: As of September 30, 2024, cash and cash equivalents were $3.53 million. Management expects current resources, combined with recent financing, to fund operations through the first half of 2025.
- Nasdaq Delisting Risk: The company received notice of non-compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) and minimum bid price requirement ($1.00). A hearing was held in October 2024, and the company is awaiting a decision. Failure to regain compliance could result in delisting.
- Strategic Pivot: Development of MB-106 (CD20 CAR T) for hematologic malignancies has been paused due to resource constraints. Current focus is on a Phase 1 investigator-sponsored trial for MB-106 in autoimmune diseases, with initiation planned for Q4 2024. Development of MB-109 (brain tumor combination therapy) is also paused pending additional resources.
- Capital Constraints: The company is subject to "baby shelf rules," limiting the amount of securities it can sell under its Form S-3 registration statement to one-third of its public float until the float exceeds $75 million.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional financing before the first half of 2025 to avoid insolvency.
- Nasdaq Listing: Monitor the outcome of the Nasdaq Hearings Panel decision regarding the equity and bid price deficiencies.
- Capital Raising Limits: Assess the impact of the "baby shelf rules" on the company's ability to raise necessary capital via public offerings.
- Asset Repurchase Liability: Review the $1.3 million deferred payment obligation to uBriGene due in June 2025, which may be extended if net assets remain below $20 million.
- Product Pipeline Viability: Evaluate the feasibility of restarting the MB-106 hematologic malignancy program given the current resource constraints and focus on autoimmune indications.